Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,666 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metabolic Complications Clear all

Conditions: Pre Diabetes, Postpartum Disorder
Interventions: Semaglutide Pen Injector [Ozempic], Placebo semaglutide pen injector; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Chronic Kidney Disease
Interventions: Sodium bicarbonate, Placebos; Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Hypertension in Pregnancy, Hypertension, Obesity
Interventions: Upper Arm Cylindrical Blood Pressure Cuff, Forearm Conical Blood Pressure Cuff; Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Nutrition Disorders, Gastrointestinal Disease, Deglutition Disorder, Feeding Difficulties, Swallowing Difficulties, Humans, Cohort Studies, Infant, Newborn, Infant, Premature, Nutrition, Pediatric Feeding Disorder, Chronic, Retrospective Studies, Breastfeeding, Mental Health Wellness, Intensive Care Units, Neonatal, Bottle Feeding
Interventions: SMART Tool for Feeding Skill Assessment; Diagnostic Test
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 22 Weeks to 42 Weeks
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Kidney Disease (CKD), Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease (CAD)
Interventions: Clopidogrel, Clopidogrel active metabolite; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Wolfram Syndrome, Diabetes Mellitus, Optic Nerve Atrophy, Deafness, Diabetes Insipidus, Ataxia
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 0 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Short Bowel Syndrome
Interventions: Somatropin, Seven Day Food Diary, Blood Tests (standard of care), Fasting, Sugar Permeability Test, Urine Collection; Drug · Procedure · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cancer Gene Mutation, Lynch Syndrome, Endometrial Cancer, Somatic Mutation
Interventions: Mismatch repair instability somatic and germline testing; Diagnostic Test
Lead sponsor: RWJ Barnabas Health at Jersey City Medical Center; Other
Eligibility: Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Jersey City, New Jersey

Conditions: Hyperkalemia
Interventions: Patiromer, Placebos; Drug
Lead sponsor: Vifor Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 133
States / cities: Alexander City, Alabama • Huntsville, Alabama • Phoenix, Arizona + 110 more

Conditions: Chronic Pain, Diabetic Neuropathies, Diabetes Mellitus
Interventions: Cebranopadol 100 µg, Cebranopadol 300 µg, Cebranopadol 600 µg, Pregabalin, Matching Placebo; Drug
Lead sponsor: Tris Pharma, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 699 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 15
States / cities: Mesa, Arizona • Garden Grove, California • Laguna Hills, California + 11 more

Conditions: Diabetes Mellitus, Type 1, Diabetes Complications
Interventions: Device specific training, Study clinician/educator visit; Device · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • The Bronx, New York

Conditions: Insulin Resistance
Interventions: Hypertonic Saline (3% NaCl), Isotonic Saline (0.9% NaCl); Other
Lead sponsor: University of Arkansas, Fayetteville; Other
Eligibility: 30 Years to 50 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Type 2 Diabetes
Interventions: Retatrutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 28
States / cities: Huntsville, Alabama • Sun City West, Arizona • Apple Valley, California + 24 more

Conditions: Childhood Obesity
Interventions: EatGrow Intervention, Delayed access; Behavioral
Lead sponsor: Texas Woman's University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Denton, Texas

Conditions: Adrenal Hyperplasia, Congenital
Interventions: Hydrocortisone sodium acetate; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 3 Years to 18 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Transfusional Iron Overload
Interventions: ICL670; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 8
States / cities: Oakland, California • Orange, California • Boston, Massachusetts + 4 more

Conditions: Zellweger Spectrum
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Iron Deficiency Anemia
Interventions: Ferumoxytol; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Hyponatremias, Water Intoxication, Inappropriate ADH Syndrome, Water-Electrolyte Imbalances
Interventions: tolvaptan, placebo matching tolvaptan; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 23
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 17 more

Conditions: Gestational Diabetes
Interventions: GlucoseMama application with blood sugar monitoring and carb monitoring., Group prenatal care for GDM.; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 51 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetic Ketoacidosis
Interventions: glargine, saline; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 6 Years to 18 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Obesity, Nephrolithiasis
Interventions: evaluation of kidney stone risk after bariatric surgery, Evaluate risk of kidney stones after bariatric surgery; Other
Lead sponsor: Indiana Kidney Stone Institute; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Prediabetes, Gestational Diabetes Mellitus, Obesity
Interventions: Weight Watchers, National Diabetes Education Program; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Kidney Transplant; Complications, Diabetes Mellitus, Type 2, Insulin Dependent Diabetes
Interventions: Dexcom G6, Dexcom G6 blinded sensor; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

Treatment to Regress to Normoglycemia in Women with a Recent History of GDM

Sodium Bicarbonate Supplementation in Chronic Kidney Disease Evaluation of Dose Response, Safety and Beneficial Effects

Conical Forearm and Cylindrical Upper Arm Non-Invasive Blood Pressure (NIBP) Measurements in Pregnant Patients

Review of Infant Oral Feeding and Skills

Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus

Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study

rHGH and Intestinal Permeability in Intestinal Failure

Lynch Syndrome Can be Diagnosed Just From Somatic Mismatch Repair Mutation

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves

Hybrid Closed Loop Effectiveness Trial in Adults With Type 1 Diabetes

The Effect of Vasopressin on Glucose Regulation

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

Eat Healthy Grow Healthy Program to Promote Fruit and Vegetable Intake in Preschoolers

Research Study for Children With Salt Wasting Congenital Adrenal Hyperplasia

A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity

Proxy-Reported Symptoms and Quality of Life Survey in Zellweger Spectrum Disorders

A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease

"SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia

Group and Mobile Care for Gestational Diabetes

Use of Insulin Glargine to Treat Diabetic Ketoacidosis

Nephrolithiasis and Bariatric Surgery

Assessing the Effectiveness of a Weight Watchers-based Lifestyle Intervention for the Primary Prevention of Type 2 Diabetes

Use of CGM in Kidney Transplant Recipients